Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Long-Term Investments (2016)

Celldex Therapeutics (CLDX) has 1 years of Long-Term Investments data on record, last reported at $1.8 million in Q4 2016.

  • For Q4 2016, Long-Term Investments changed N/A year-over-year to $1.8 million; the TTM value through Dec 2016 reached $1.8 million, changed N/A, while the annual FY2016 figure was $1.8 million, N/A changed from the prior year.
  • Long-Term Investments reached $1.8 million in Q4 2016 per CLDX's latest filing.
  • Across five years, Long-Term Investments topped out at $1.8 million in Q4 2016 and bottomed at $1.8 million in Q4 2016.